Recombinant polyclonal drug trial for HBV gets FDA green light
Drug Discovery World
AUGUST 7, 2024
With over 1,000 different HBV-targeted antibodies in the mixture, GIGA-2339 is unlike any therapy currently in development. We look forward to initiating our trial in late 2024 and showcasing the clinical potential of our recombinant polyclonal antibody platform, starting with HBV.”
Let's personalize your content